[Current approaches to the problem of correcting hyper-IgE antibody production].
D000818:Animals; D000941:Antigens / Q000008:administration & dosage; D003888:Desensitization, Immunologic / Q000379:methods; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D007073:Immunoglobulin E / Q000096:biosynthesis*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007375:Interleukin-1 / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D051381:Rats; D013951:Thymus Hormones / Q000627:therapeutic use; D014165:Transfer Factor / Q000627:therapeutic use
D000941:Antigens; D007166:Immunosuppressive Agents; D007375:Interleukin-1; D013951:Thymus Hormones; D014165:Transfer Factor; D007978:Levamisole; D007073:Immunoglobulin E
Sovremennye podkhody k probleme korrektsii giper-IgE antitelogeneza.